An observational study in Atrial Fibrillation, Tachycardia, Supraventricular and Bradyarrhythmia, sponsored by HelpWear Inc.. Completed at 1 site in Canada. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by HelpWear Inc. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.
Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 56th largest by enrollment of the 57 observational ones that give a count, is one of 18 that started in 2020, is one of 57 observational ones, and was the 260th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:
Milestone Pharmaceuticals Inc. · Sites in Canada, United States, Netherlands
Ages 18+
Regeneron Pharmaceuticals · Sites in Canada, United States, Japan
Ages 18+
Pavel Antiperovitch · Sites in Canada
Ages 18+
French Cardiology Society · Sites in Canada, France, New Zealand
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
318 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 29 · Phase 3 64 · Phase 4 30
First in 1999; this study’s year is marked. 18 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 282 across the 261 interventional studies, 297 across the 57 observational. Of the 217 that completed or were terminated, 81 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
128 of 318 have an industry lead sponsor. The 10 most frequent:
HelpWear Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
HelpWear Inc. has 2 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
24 of the studies in Atrial Fibrillation with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT02150902Ottawa Heart Institute Research CorporationAugmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence | 2026-11-27 |
| NCT07245147Jacqueline JozaREDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention | 2026-12 |
| NCT06249269Ratika ParkashReversal of Atrial Substrate to Prevent Atrial Fibrillation Cohort Study | 2026-12 |
| NCT05600829University of CalgaryA Behavioural Weight Loss Intervention Delivered in Cardiac Rehabilitation for Patients With Atrial Fibrillation and Obesity | 2026-12-30 |
Add all 24 to your calendar (.ics) → With an account.
Among the 318 studies in Atrial Fibrillation with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The clinical study is intended to implement and test the collection and analysis of paired ECG data from the HeartWatch and two comparator devices, an Event Recorder and Holter. The HeartWatch is indicated for extended diagnostic evaluation of patients with transient symptoms of possible cardiac origin such as syncope and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. While the use of the device itself can be managed by both healthcare professionals and patients, interpretation of the collected data for diagnosis is restricted to healthcare professionals, as the data must be loaded and analyzed separately after recording. Patients indicated for extended ambulatory ECG testing will be approached for participation. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours or the HeartWatch and Holter monitor for up to 48 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data, while Holter subjects will record diary information on their activities and any relevant symptoms. Adverse events and user preference for one device versus the other being used in that arm will also be collected from all subjects. Paired ECG data from the HeartWatch and comparator devices is expected to be similar in terms of the events documented and the proportion of data that is clinically interpretable.
Consecutive patients referred to participating clinics for extended ambulatory ECG testing. Subjects referred for extended ambulatory ECG testing will be recruited from the Toronto Heart Centre. Referring physicians will be asked to indicate if longer-term (i.e., Event Recorder) or shorter-term monitoring (i.e., Holter monitor) is desired for a given patient.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 40 patients will be enrolled in Arm A. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data.
Device: HeartWatch · Device: Event Recorder
Up to 10 patients will be enrolled in Arm B.Subjects will wear the HeartWatch and Holter monitor for up to 48 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Holter subjects will record diary information on their activities and any relevant symptoms.
Device: HeartWatch · Device: Holter Monitor
The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.
A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.
A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.
Pairing HeartWatch and Event Recorder
Can paired user-triggered (tagged) and auto-triggered ECG data from the HeartWatch and Event Recorder be successfully collected?
Time frame: Up to 6 months, with 3 months of analysis time (9 months total)
Pairing HeartWatch and Holter
Can paired continuous ECG data from the HeartWatch and Holter monitor be successfully collected?
Time frame: Up to 6 months, with 3 months of analysis time (9 months total)
Body Position and Activity
Does body position and activity affect the quality of the HeartWatch, Event Recorder, and Holter data?
Time frame: Up to 6 months, with 3 months of analysis time (9 months total)
Adverse Events
Incidence of adverse events among the HeartWatch and comparator devices and the types of adverse events
Time frame: Up to 6 months, with 3 months of analysis time (9 months total)
User Preferences
User preferences of subjects with the HeartWatch versus the comparator devices
Time frame: Up to 6 months, with 3 months of analysis time (9 months total)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2020 to primary completion in Oct 2023, 34 months.
Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 34 months is above that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.